Biphasic hyalinizing psammomatous renal cell carcinoma - Revision history

Michael at 17:57, 25 March 2024

2024-03-25T17:57:28Z

← Older revision		Revision as of 17:57, 25 March 2024
Line 5:		Line 5:
	\| Caption =		\| Caption =
	\| Synonyms =		\| Synonyms =
	\| Micro = biphasic cytomorphology (small cells and large cells), hyaline stroma, [[psammoma bodies]]		\| Micro = biphasic cytomorphology (small cells and large cells), hyaline stroma, [[psammoma bodies]]
	\| Subtypes =		\| Subtypes =
	\| LMDDx = [[TFEB renal cell carcinoma]], [[papillary renal cell carcinoma]], [[FH-deficient renal cell carcinoma]]		\| LMDDx = [[TFEB renal cell carcinoma]], [[papillary renal cell carcinoma]], [[FH-deficient renal cell carcinoma]]

Michael at 17:56, 25 March 2024

2024-03-25T17:56:11Z

← Older revision		Revision as of 17:56, 25 March 2024
Line 1:		Line 1:
			{{ Infobox diagnosis
			\| Name = {{PAGENAME}}
			\| Image =
			\| Width =
			\| Caption =
			\| Synonyms =
			\| Micro = biphasic cytomorphology (small cells and large cells), hyaline stroma, [[psammoma bodies]]
			\| Subtypes =
			\| LMDDx = [[TFEB renal cell carcinoma]], [[papillary renal cell carcinoma]], [[FH-deficient renal cell carcinoma]]
			\| Stains =
			\| IHC = merlin loss of staining, [[HNF-1beta]] +ve, [[PAX8]] +ve, [[CK7]] +ve, EMA +ve, AMACR +ve, WT1 -ve, Melan A -ve, HMB-45 -ve, [[GATA3]] -ve
			\| EM =
			\| Molecular = neurofibromin 2 mutations
			\| IF =
			\| Gross =
			\| Grossing =
			\| Staging =
			\| Site =
			\| Assdx =
			\| Syndromes =
			\| Clinicalhx =
			\| Signs =
			\| Symptoms =
			\| Prevalence =
			\| Bloodwork =
			\| Rads =
			\| Endoscopy =
			\| Prognosis =
			\| Other =
			\| ClinDDx =
			\| Tx =
			}}
	'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|authors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>		'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|authors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>

Line 19:		Line 51:
	*[[TFEB renal cell carcinoma]].		*[[TFEB renal cell carcinoma]].
	*[[Papillary renal cell carcinoma]].		*[[Papillary renal cell carcinoma]].
			*[[FH-deficient renal cell carcinoma]].

	==IHC==		==IHC==

Michael at 17:52, 25 March 2024

2024-03-25T17:52:13Z

← Older revision		Revision as of 17:52, 25 March 2024
Line 1:		Line 1:
	'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|authors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>		'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|authors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>

			It is not recognized as a subtype of RCC by the WHO of 2022.<ref name=pmid35971742/>

	==General==		==General==

Michael: more

2024-03-25T17:50:58Z

← Older revision		Revision as of 17:50, 25 March 2024
Line 33:		Line 33:
	*FH normal.		*FH normal.
	*SDHB normal.		*SDHB normal.

			Others:
			*Merlin - loss of staining (12 of 13 cases<ref name=pmid35971742>{{cite journal \|authors=Collins K, Hwang M, Antic T, Paintal A, Argani P, Matoso A, Gopinath A, Baskovich B, Mehra R, Williamson SR, Idrees MT, Barletta JA, Anderson WJ, Hirsch MS, Hornick JL, Acosta AM \|title=Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma \|journal=Histopathology \|volume=81 \|issue=5 \|pages=577–586 \|date=November 2022 \|pmid=35971742 \|doi=10.1111/his.14731 \|url=}}</ref>).

			==Molecular==
			*Neurofibromin 2 (NF2) gene mutations.<ref name=pmid35971742/>

	==See also==		==See also==

Michael: /* IHC */

2021-10-14T15:44:37Z

IHC

← Older revision		Revision as of 15:44, 14 October 2021
Line 33:		Line 33:
	*FH normal.		*FH normal.
	*SDHB normal.		*SDHB normal.

			==See also==
			*[[Renal cell carcinoma, unclassified]].
			*[[Kidney tumours]].

	==References==		==References==

Michael: /* Microscopic */

2021-10-14T15:44:16Z

Microscopic

← Older revision		Revision as of 15:44, 14 October 2021
Line 11:		Line 11:
	*#Small cells.		*#Small cells.
	*#Large cells.		*#Large cells.
			*Hyaline stroma.
	*[[Psammoma bodies]].		*[[Psammoma bodies]].

	DDx:		DDx:
	*[[TFEB renal cell carcinoma]].		*[[TFEB renal cell carcinoma]].
			*[[Papillary renal cell carcinoma]].

	==IHC==		==IHC==

Michael: /* IHC */

2021-10-13T05:16:01Z

IHC

← Older revision		Revision as of 05:16, 13 October 2021
Line 18:		Line 18:
	==IHC==		==IHC==
	Features:<ref name=pmid32217839/>		Features:<ref name=pmid32217839/>
	*HNF-1beta +ve		*[[HNF-1beta]] +ve
	*PAX8 +ve		*[[PAX8]] +ve
	*CK7 +ve		*[[CK7]] +ve
	*EMA +ve.		*EMA +ve.
	*AMACR +ve.		*AMACR +ve.
Line 26:		Line 26:
	*Melan A -ve.		*Melan A -ve.
	*HMB-45 -ve.		*HMB-45 -ve.
	*GATA3 -ve.		*[[GATA3]] -ve.
	*Chromogranin A -ve.		*Chromogranin A -ve.
	*Synaptophysin -ve.		*Synaptophysin -ve.

Michael at 05:12, 13 October 2021

2021-10-13T05:12:38Z

← Older revision		Revision as of 05:12, 13 October 2021
Line 1:		Line 1:
	'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|~~vauthors~~=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>		'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|authors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>

	==General==		==General==

Michael: /* Microscopic */

2021-10-13T05:12:12Z

Microscopic

← Older revision		Revision as of 05:12, 13 October 2021
Line 1:		Line 1:
	'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|vauthors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>		'''Biphasic hyalinizing psammomatous renal cell carcinoma''', abbreviated '''BHP RCC''', is a rare type of [[renal cell carcinoma]] with mutations in neurofibromin 2.<ref name=pmid32217839>{{cite journal \|vauthors=Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN \|title=Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations \|journal=Am J Surg Pathol \|volume=44 \|issue=7 \|pages=901–916 \|date=July 2020 \|pmid=32217839 \|pmc=7350624 \|doi=10.1097/PAS.0000000000001467 \|url=}}</ref>

			==General==
			*Evolving entity.
			*Very rare.
			*Prevalence: male > female.

	==Microscopic==		==Microscopic==

Michael at 02:42, 13 October 2021

2021-10-13T02:42:03Z

← Older revision		Revision as of 02:42, 13 October 2021
Line 2:		Line 2:

	==Microscopic==		==Microscopic==
	Features:		Features:<ref name=pmid32217839/>
	*Biphasic cytomorphology:		*Biphasic cytomorphology:
	*#Small cells.		*#Small cells.
Line 10:		Line 10:
	DDx:		DDx:
	*[[TFEB renal cell carcinoma]].		*[[TFEB renal cell carcinoma]].

			==IHC==
			Features:<ref name=pmid32217839/>
			*HNF-1beta +ve
			*PAX8 +ve
			*CK7 +ve
			*EMA +ve.
			*AMACR +ve.
			*WT1 -ve
			*Melan A -ve.
			*HMB-45 -ve.
			*GATA3 -ve.
			*Chromogranin A -ve.
			*Synaptophysin -ve.
			*FH normal.
			*SDHB normal.

	==References==		==References==